From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
This article was originally published in PharmAsia News
Executive Summary
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services
You may also be interested in...
WuXi Venture Fund Managing Director Sofie Qiao On Taking Risks: An Interview With PharmAsia News
WuXi AppTec Inc. has largely invested along with established venture funds since its launch in 2011 backed by $50 million of investor funds. But the humble student aims to evolve and invest more boldly, says newly appointed managing director Sofie Qiao.
Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs
Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.
Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs
Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.